关注
Darren Moss
Darren Moss
Senior Scientist, Janssen Pharmaceutica
在 its.jnj.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Antimalarial pharmacology and therapeutics of atovaquone
GL Nixon, DM Moss, AE Shone, DG Lalloo, N Fisher, PM O'Neill, SA Ward, ...
Journal of Antimicrobial Chemotherapy 68 (5), 977-985, 2013
2052013
Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1
MJ Capper, PM O’Neill, N Fisher, RW Strange, D Moss, SA Ward, ...
Proceedings of the National Academy of Sciences 112 (3), 755-760, 2015
1242015
Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling
DM Moss, M Siccardi
British journal of pharmacology 171 (17), 3963-3979, 2014
1142014
The role of drug transporters in the kidney: lessons from tenofovir
DM Moss, M Neary, A Owen
Frontiers in pharmacology 5, 248, 2014
932014
Antitubercular pharmacodynamics of phenothiazines
AJ Warman, TS Rito, NE Fisher, DM Moss, NG Berry, PM O'Neill, SA Ward, ...
Journal of Antimicrobial Chemotherapy 68 (4), 869-880, 2013
742013
Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir
DM Moss, WS Kwan, NJ Liptrott, DL Smith, M Siccardi, SH Khoo, DJ Back, ...
Antimicrobial agents and chemotherapy 55 (2), 879-887, 2011
712011
Divalent Metals and pH Alter Raltegravir Disposition In Vitro
DM Moss, M Siccardi, M Murphy, MM Piperakis, SH Khoo, DJ Back, ...
Antimicrobial agents and chemotherapy 56 (6), 3020-3026, 2012
662012
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer
E de Wolf, MI Abdullah, SM Jones, K Menezes, DM Moss, FP Drijfhout, ...
Scientific reports 7 (1), 5410, 2017
602017
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T> C polymorphism
M Siccardi, A D'Avolio, S Nozza, M Simiele, L Baietto, FR Stefani, D Moss, ...
Pharmacogenetics and genomics 20 (12), 759-765, 2010
582010
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
M Giardiello, NJ Liptrott, TO McDonald, D Moss, M Siccardi, P Martin, ...
Nature communications 7 (1), 13184, 2016
572016
Nanotechnologies in pancreatic cancer therapy
A Manzur, A Oluwasanmi, D Moss, A Curtis, C Hoskins
Pharmaceutics 9 (4), 39, 2017
522017
Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis
WD Hong, PD Gibbons, SC Leung, R Amewu, PA Stocks, A Stachulski, ...
Journal of Medicinal Chemistry 60 (9), 3703-3726, 2017
492017
The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery
DM Moss, P Curley, H Kinvig, C Hoskins, A Owen
Expert Review of Gastroenterology & Hepatology 12 (3), 223-236, 2018
432018
Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation
P Curley, RKR Rajoli, DM Moss, NJ Liptrott, S Letendre, A Owen, ...
Antimicrobial agents and chemotherapy 61 (1), 10.1128/aac. 01841-16, 2017
412017
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro
DM Moss, NJ Liptrott, P Curley, M Siccardi, DJ Back, A Owen
Antimicrobial agents and chemotherapy 57 (11), 5612-5618, 2013
402013
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting
M Siccardi, A D'Avolio, S Rodriguez-Novoa, L Cuenca, M Simiele, ...
Therapeutic drug monitoring 34 (2), 232-235, 2012
392012
Predicting intestinal absorption of raltegravir using a population-based ADME simulation
DM Moss, M Siccardi, DJ Back, A Owen
Journal of Antimicrobial Chemotherapy 68 (7), 1627-1634, 2013
352013
The application of nanotechnology to drug delivery in medicine
TO McDonald, M Siccardi, D Moss, N Liptrott, M Giardiello, S Rannard, ...
Nanoengineering, 173-223, 2015
282015
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study
RKR Rajoli, AT Podany, DM Moss, S Swindells, C Flexner, A Owen, ...
The International Journal of Tuberculosis and Lung Disease 22 (8), 937-944, 2018
242018
Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
DM Moss, NJ Liptrott, M Siccardi, A Owen
Frontiers in pharmacology 6, 78, 2015
232015
系统目前无法执行此操作,请稍后再试。
文章 1–20